Review for 10.1186/s12876-021-01948-6 (2021)

Reviewer’s report
Title: 
Development of pulmonary sarcoidosis in Crohn’s disease patient under
infliximab biosimilar treatment after long-term original infliximab treatment: A
case report and literature review.
Version: 
0 
Date: 
22 Aug 2021
Reviewer's report:
Summary: This case report with literature review depicts a case of pulmonary
sarcoidosis in a patient with Crohn's disease oninfliximab biosimilar. It also
provides a review about all patients developing sarcoidosis on TNF-I. Overall, it
is wellwritten but do requires somemodifications.   
Major: 
1. Authors tried to argue that the switching from the O-IFX to IFX-BS might
contribute to the sarcoidosis development. Discussing potential
molecular/cellular mechanisms under the occurence of pulmonary sarcoidosis
from using TNF-I biosimilar is recommended.   
2. The 7 cases with CD in your literature review are quite important and
frequently mentioned in your manuscript. Kindly provide a table with
the information of the 7 cases in the main text other than placing them in the
supplement form.   
Minor: 
1. To follow the journal's policy, the abstract needs to be structured into
background, case presentations, and conclusions; and the subtitle of the first part
of the main text should be changed from introduction to background.   
2. In the case presentation, kindly mention the ethnicity, medical history, and
pertinent family history of the patient, which might be relevant in the occurrence
of sarcoidosis.   
3. Kindly provide the reason for switching from O-IFX to IFX-BS.  
4. Anti-nuclear antibody titer is often reported as a ratio, such as 1:160. Please
consider changing the format. (P7L28)  
5. The patient was followed up for four months after the discontinuation of TNF-
I, which might not be sufficient enough to observe the recurrence of Crohn's
disease. Do we have information after a longer follow-up duration?   
6. The median duration to the development of sarcoidosis in CD patients under
ADA without switching regimen should be 24, not 34 months, based on the
information listed in the supplemental form. (P10L55-P11L1)  
7. In the case 5 (reference 7), the patient was treated with topical corticosteroid
for the skin lesion, which persisted despite the treatment. Please modify the
description in the manuscript to make it more accurate and complete. (P11L26-
L30).
Publons Reviewer Recognition
. Springer Nature can send verification of this
review directly to Publons (a subsidiary of Clarivate Analytics). If you would
like to take advantage of this service, please click on the “Yes” option below.
Your name, email address, title of the reviewed manuscript, name of the journal,
and date of your review submission (the “Review Data”) will then be transmitted
to Publons after the final decision on the manuscript has been made. If you have
already registered at Publons, they will notify you of the receipt of this review
and update your profile 
as per your settings and their policy. If you are not
registered with Publons, you will receive an email from them asking you to
register in order for them to be able to recognize your review on your new
profile page. Publons may use the Review Data to generate derivative metadata
for the benefit of Publons and you as a reviewer, carefully considering the
sensitivity of such information. For example, Publons may verify your record as
a reviewer by updating your profile published on its webservice if you have
registered for such service or help editors to identify candidate reviewers. Please
find the details of processing in Publons’ privacy policy
https://publons.com/about/terms
Yes
Declaration of competing interests
Please complete a declaration of competing
interests, considering the following questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests.
Reviewer Publication Consent.
 I agree for my report to be made available
under an Open Access Creative Commons CC-BY License (
http://creativecommons.org/licenses/by/4.0
) if this manuscript is accepted for
publication. Any comments that I do not wish to be included in the published
report have been included as confidential comments to the editor, which will not
be published.
If you are not happy for us to publish this report, please contact the
editorial office before completing the review.
If you wish, you can include your
name in your published report. Please note you must decide whether to include
your name at the start of the process and confirm this decision whenever
prompted. If you change your decision later, we will not be able to publish your
name.
I agree to the terms of the CC-BY 4.0 license; please 
do not
 publish my name
with my report. (default)
Is the study design appropriate to answer the research question (including the use
of appropriate controls), and are the conclusions supported by the evidence
presented?
Yes
Are the methods sufficiently described to allow the study to be repeated?
Yes
Is the use of statistics and treatment of uncertainties appropriate?
Yes
Is the presentation of the work clear?
Yes
Are the images in this manuscript (including electrophoretic gels and blots) free
from apparent manipulation?
Yes